• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Ambit Biosciences

edit

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit’s lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit’s clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Recent Milestones

edit

• 
  Ambit Biosciences received $50M in Venture Round funding. (11/6/12)
  Posted 11/7/12 at 3:16am via yahoo.com
• 
  Ambit Biosciences received $30M in Series D funding. (6/10/11)
  Posted 6/10/11 at 6:24pm via ambitbio.com
• 
  Ambit Biosciences added Alan Lewis as President & CEO.
  Posted 6/10/11 at 6:24pm
• 
  Ambit Biosciences added Alan Fuhrman as CFO.
  Posted 6/10/11 at 6:24pm
• 
  Ambit Biosciences added Christopher J. Morl as COO.
  Posted 6/10/11 at 6:24pm

Videos

Screenshots

edit

Sources

1. AMBIT BIOSCIENCES COMPLETES $30 MILLION SERIES D-2 FINANCING (ambitbio.com) [edit]
2. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia (finance.yahoo.com) [edit]